Advertisement

Topics

Companies Related to "Cancer Stem Cells Hedge Their Bets with Noncanonical" [Most Relevant Company Matches] RSS

14:02 EST 13th November 2018 | BioPortfolio

Here are the most relevant search results for "Cancer Stem Cells Hedge Their Bets with Noncanonical" found in our extensive corporate database of over 50,000 company records.

Showing "Cancer Stem Cells Hedge Their Bets with Noncanonical" Companies 1–25 of 3,000+

Extremely Relevant

Minerva Biotechnologies

Minerva Biotechnologies is a pioneer in the field of stem cells and cancer stem cells. Minerva was first to discover that cancer cells hijack an otherwise normal stem cell growth mechanism, involving a growth factor receptor called MUC1* (pronounced muk 1 star). By studying human stem cells in parallel with human cancer cells, Minerva scientists figured ou...


OncoMed Pharmaceuticals Inc.

OncoMed Pharmaceuticals is pioneering the development of novel therapeutics that target a new class of solid tumor cells, known as "cancer stem cells". The company's technology is based on a recent discovery by its co-founders that cancer stem cells are uniquely responsible for the growth and proliferation of tumors. We are leveraging our advanced understanding of cancer stem cells to identify the...

Verastem, Inc.

Verastem, Inc. (NASDAQ: VSTM) is a clinical-stage biopharmaceutical company focused on discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: F...


Verastem, Inc. Verastem, Inc.

Verastem, Inc. (NASDAQ:VSTM) is discovering and developing drugs to treat cancer by the targeted killing of cancer stem cells. Cancer stem cells are an underlying cause of tumor recurrence and metastasis. Verastem is developing small molecule inhibitors of signaling pathways that are critical to cancer stem cell survival and proliferation: FAK, PI3K/mTOR a...

Cellectis Group

Cellectis stem cells, is a business unit within the Cellectis group and is a global leader in stem cell technology. Cellectis stem cells, created in November 2011 from Cellartis AB and Ectycell SAS, possesses broad expertise in pluripotent stem cells, including iPS cell technology, genetic engineering and specialised cells. Cellectis stem cells is developi...

Relevant

Cellerant Therapeutics, Inc.

Embryonic Stem Cells are derived from early-stage embryos before mature organs and tissues have developed. Embryonic stem cells have the greatest potential for both self-renewal (creating large numbers of stem cells) and differentiation into many different types of mature cells (bone, muscle, blood, brain, etc.)

Forever Labs

Forever Labs is the first company to bank young adult stem cells, so you can live a healthier and longer life. Research on stem cells suggest that as you age, you lose stem cells and the ones that remain become damaged and less effective. As a longevity company and an educational force in stem cell research, Forever Labs is transforming the healthcare indu...

Vitro Diagnostics, Inc.

Vitro Diagnostics, Inc., dba Vitro Biopharma (OTCBB: VODG) (http://www.vitrobiopharma.com), owns U.S. patents for production of a fertility drug, immortalization of pituitary cells, and a cell line that produces beta islets for use in treatment of diabetes. Vitro’s mission is “Harnessing the Power of Cells™” for the advancement of regenerative...

Fate Therapeutics Inc.

Founded in 2007 on the leading stem cell and developmental biology research, Fate Therapeutics is using the fundamental biological mechanisms that guide cell fate to develop stem cell therapeutics. The company has brought together the foremost scientists from the nation’s research hotbeds (Boston, San Francisco, San Diego and Seattle) who have demonstrated the potential to create and modulate st...

Life Stem Genetics Inc.

Life Stem Genetics (“LSG”) is a progressive health care company that focuses on healing with a patient’s own “Stem Cells”. Stem Cells for years have been known to heal a variety of ailments successfully and now it is being offered as an efficient and painless way to treat many different illnesses ranging from orthopedic Injuries, neurolog...

Stem Cell Sciences plc

Stem Cell Sciences plc (AIM:STEM, ASX:STC), a company focused on the commercialisation of stem cells and stem cell technologies, is pleased to announce that two independent laboratories in the UK and USA have achieved germ-line transmission from embryonic stem (ES) cells in rats using technologies exclusively licensed to the company by Edinburgh University. This is believed to be the first tim...

R-JAPAN Co., Ltd.

R-JAPAN Co., Ltd. is the advanced biotechnology company specialized in manufacturing mesenchymal stem cells regenerative therapy with stem cell technology of Biostar Stem cell Research Institute in Korea. R-Japan’s proprietary technology is to isolate, multiply, and store adult mesenchymal stem cells with ensuring genetic integrity. R-Japan currently ...

AlphaMed Press

AlphaMed Press publishes the internationally renowned journals, "Stem Cells" and "The Oncologist." "Stem Cells," now in its 27th year, is the oldest and one of the world's top-tier peer-reviewed monthly journals in the fast-paced area of stem cells and regenerative medicine. "The Oncologist," in its 14th year, is a premier peer-reviewed monthly journal dedicated to physicians entrusted with the c...

Vitro Diagnostics

We develop stem cell technology for potential use in diabetes research and treatment. Our research has led to a patent-pending method for generation of adult stem cells from cells isolated from tissues. While embryonic stem cells are capable of differentiation into all of the various cells of the body, adult stem cells are more limited in differentiation capacity generally including the cell typ...

Stemline Therapeutics, Inc.

Stemline Therapeutics, Inc. is a clinical stage biotechnology company developing novel oncology compounds directed to cancer stem cell targets. Stemline's lead compound, SL-401, targets the interleukin-3 receptor which is expressed on multiple hematological cancers including leukemia blasts and leukemia cancer stem cells. SL-401 has demonstrated single agent anti-tumor activity at tolerable doses ...

Gilbert, Arizona Economic Development Division

Gilbert, Arizona announces new cancer research and treatment center and stem cell research and treatment center. Banner Health has joined with MD Anderson to deliver unprecedented levels of cancer care at the new Banner MD Anderson Cancer Center in Gilbert, Arizona. This unique collaboration represents the broadest extension of MD Anderson’s cancer ca...

StemBioSys, Inc.

Stem cells are the future of medicine. We are the future of stem cells. StemBioSys is located in San Antonio, Texas, proximate to the University of Texas Health Science Center at San Antonio from which we have licensed proprietary and disruptive technology for the enhanced isolation, growth, and delivery of stem cells for research, diagnostic and therapeut...

International Society for Stem Cell Research

The International Society for Stem Cell Research is an independent, nonprofit membership organization established to promote and foster the exchange and dissemination of information and ideas relating to stem cells, to encourage the general field of research involving stem cells and to promote professional and public education in all areas of stem cell res...

NeoStem, Inc.

NeoStem, Inc. continues to develop and build on its core capabilities in cell therapy, capitalizing on the paradigm shift that we see occurring in medicine. In particular, we anticipate that cell therapy will have a significant role in the fight against chronic disease and in lessening the economic burden that these diseases pose to modern society. We are emerging as a technology and market lead...

StemSource Incorporated

Stem cells are uniquely "unprogrammed" cells that give rise to all other cells in our bodies. They are important because they offer a potential source of replacement cells and tissues that are able to treat a myriad of disorders including neurologic diseases such as Parkinson's, Alzheimer's, spinal cord injury, and stroke, tissue loss or injury, heart disease, diabetes and arthritis.Millions of Am...

OncoMed Pharmaceuticals, Inc.

OncoMed is a clinical development-stage biopharmaceutical company focused on discovering and developing first-in-class monoclonal antibody therapeutics targeting cancer stem cells, or CSCs. Our approach has been to target CSCs, which are the subpopulation of cells in a tumor responsible for driving growth and metastasis of the tumor. CSCs, also known as tumor-initiating cells, exhibit certain pr...

Epistem Plc

Epistem is a biotechnology company commercialising its expertise in epithelial stem cells in the areas of oncology, gastrointestinal and dermatological diseases. Epistem develops innovative therapeutics and biomarkers and provides contract research services to drug development companies. The Group's expertise is focused on the regulation of adult stem cells located in epithelial tissue, which ...

TriStem

The TriStem Group has been set up by Mr.Ghazi Dhoot and Dr. Ilham Saleh Abuljadayel to further research and develop its retrodifferentiation technology which is used to create stem cells from mature adult cells. The retrodifferentiation technology is based on the results of 12 years of research and currently TriStem is the only company that owns, and is in the process of commercialising, this tech...

Agilvax

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critic...

Agilvax, Inc.

Agilvax discovers and develops targeted cancer immunotherapies and vaccines with its proprietary virus-like particle (VLP) platform technology. Agilvax’s lead product, AX09, is being developed as an immunotherapy for triple-negative breast cancer (TNBC) by targeting cancer stem cells. TNBC has a high frequency of cancer stem cells, which play a critic...


More From BioPortfolio on "Cancer Stem Cells Hedge Their Bets with Noncanonical"

Advertisement
Quick Search
Advertisement
Advertisement

 

Corporate Database Quicklinks